The Study of [14C] GZR18

Summary

This trial is a Single-center, non-randomized, open-label, single-dose Mass Balance Study. The study period of each subject consists of a screening period (D-21 to D-2), a baseline period (D-2 to D-1), a dosing and routine collection period (D1 to D36) and an intermittent collection and follow-up period (D36 to D78, during which subjects should visit the hospital once a week, 6 visits in total).

Timeline

Start

2025-05-07

Primary completion

2025-08-13

Completion

2025-08-13

Drugs

Indications